文献速递乳房整形与再造美容整形

自体脂肪移植用于乳房增大与重塑:并发症、影像学结局、脂肪保留率及患者满意度的系统综述与荟萃分析

Autologous Fat Grafting for Breast Augmentation and Breast Remodeling: A Systematic Review and Meta-analysis of Complications, Radiologic Outcomes, Graft Retention, and Patient-Reported Satisfaction.
PubMed 文献 · Aesthet Surg J · 2026-09-05

该系统综述与荟萃分析纳入40项原始临床研究共5684例患者,评估自体脂肪移植用于乳房增大与重塑的并发症、影像学结局、脂肪保留率及患者满意度。汇总并发症率为25.9%(95%CI 22.4-29.6),以脂肪坏死最常见;观察性证据支持较好的安全性,但肿瘤学结局未定量合并,需前瞻性对照研究。

要点

  • 汇总并发症率25.9%,以脂肪坏死等轻微影像学或可触及异常为主。
  • 患者满意度93.1%,但患者报告结局指标异质性大。

核心结论

  • 当前观察性证据支持自体脂肪移植用于乳房增大与重塑具有较好的安全性,但肿瘤学结局未定量合并。

研究设计与样本

  • 遵循PRISMA 2020的系统综述与荟萃分析,纳入40项原始临床研究共5684例患者。
  • 偏倚风险评估采用RoB2、ROBINS-I和纽卡斯尔-渥太华量表。
  • 随机效应荟萃分析以限制性最大似然估计为主模型,采用Hartung-Knapp调整,敏感性分析使用DerSimonian-Laird和Paule-Mandel估计量。
  • 平均随访时间超过6个月。

主要发现

  • 汇总并发症率为25.9%(95%CI 22.4-29.6),脂肪坏死为最常见不良事件。
  • 良性影像学发现包括脂肪坏死(8.8%)和钙化(1.1%),无证据显示癌症检测受损。
  • 每侧乳房平均注射脂肪体积为310 mL。
  • 患者满意度为93.1%(95%CI 90.4-95.8),但患者报告结局指标异质性大。

关键数值与推荐

  • 并发症异质性显著(I2=78%;τ2=0.021;Q=177.6;p<0.001)。
  • 体积保留率异质性显著(I2=82%;τ2=0.067;Q=216.4;p<0.001)。
  • 影像学结局异质性中等(I2=52%;τ2=0.008;Q=81.3;p<0.001)。

临床怎么用

  • 可参考汇总并发症率与脂肪坏死风险进行术前咨询和术后影像随访规划。
  • 患者满意度较高,可用于预期管理,但应告知肿瘤学结局尚未定量合并。

局限性

  • 肿瘤学结局未定量合并。
  • 并发症、体积保留率和影像学结局均存在显著异质性,反映技术、影像、处理、富集、评估方法和随访的差异。
  • 需要前瞻性对照研究及标准化报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autologous fat grafting (AFG) is increasingly used for aesthetic breast augmentation and remodeling because it provides natural tissue augmentation without permanent implants. This systematic review and meta-analysis evaluated complications, radiologic outcomes, graft retention, and patient satisfaction following AFG. A PRISMA 2020-compliant search identified 40 primary clinical studies including 5,684 patients. The risk of bias was assessed using the RoB2, ROBINS-I, and Newcastle-Ottawa Scale. Random-effects meta-analysis used restricted maximum likelihood estimation as the primary model, with Hartung-Knapp adjustment and DerSimonian-Laird and Paule-Mandel estimators in sensitivity analyses. Mean follow-up exceeded 6 months. The pooled complication rate was 25.9% (95% CI, 22.4-29.6), mainly consisting of minor radiologic or palpable findings; fat necrosis was the most common adverse event. Benign radiologic findings included fat necrosis (8.8%) and calcifications (1.1%), without evidence of impaired cancer detection. Mean injected fat volume was 310 mL per breast. Twelve-month volume retention was 61.3% (95% CI, 57.1-65.4), with higher retention in SVF/PRP-enriched grafts (68.9% vs 56.1%; p<0.01), although evidence remained heterogeneous. Patient satisfaction was 93.1% (95% CI, 90.4-95.8), despite heterogeneous PROMs. Heterogeneity was substantial for complications (I2=78%; τ2=0.021; Q=177.6; p<0.001) and volume retention (I2=82%; τ2=0.067; Q=216.4; p<0.001), and moderate for radiologic outcomes (I2=52%; τ2=0.008; Q=81.3; p<0.001), reflecting variability in techniques, imaging, processing, enrichment, assessment methods, and follow-up. Current observational evidence supports favorable safety profiles; however, oncologic outcomes were not quantitatively pooled, and prospective comparative studies with standardized reporting are required.

来源:Aesthet Surg J,查看原文。版权归原作者所有。

引用

  1. Gentile P, Sterodimas A. Autologous Fat Grafting for Breast Augmentation and Breast Remodeling: A Systematic Review and Meta-analysis of Complications, Radiologic Outcomes, Graft Retention, and Patient-Reported Satisfaction. Aesthet Surg J. 2026. PMID: 42697558. doi:10.1093/asj/sjag187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。